Since both preeclamptic patients and those receiving VEGF inhibitors are in the condition of disturbed physiological angiogenesis, these soluble factors are likely to reflect endothelial dysfunction in both processes [21]. The gene discussed is VEGFA; the disease is endothelial dysfunction.